Skip to content

Vestibular Evaluation After Vestibular Schwannoma Treatment

Vestibular Evaluation Before and After Treatment of Vestibular Schwannoma. Comparison of Gamma Knife Radiosurgery and Microsurgical Resection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03670589
Acronym
EVTSVCGEC
Enrollment
51
Registered
2018-09-13
Start date
2018-06-28
Completion date
2018-08-24
Last updated
2018-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dizziness

Keywords

vestibular schwannoma, gammaknife radiosurgery, vestibular evaluation

Brief summary

Vestibular schwannoma is a benign tumor located on the vestibular nerve. Patient could present dizziness symptoms cause to the tumor, and at least after the treatment by gamaknife radiosurgery or microsurgery resection. Only few studies keep the interest about dizziness symptoms and treatment modality in vestibular schwannoma. In the study dizziness symptoms were compared before and after the treatment of vestibular schwannoma by radiosurgery gammaknife or microsurgery resection. 2 scales were used : dizziness handicap inventory (DHI) and dizziness functionnal scale (AAO).

Interventions

RADIATIONRadiosurgery gammaknife

This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor

PROCEDUREMicrosurgery resection

Classical surgical approach with oto-neurosurgery procedures

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient treated of an one side vestibular schwannoma between 01/01/2012 and 31/12/2017, follow at the Grenoble University Hospital * treatment : gamaknife radiosurgery or microsurgery resection * no opposition of the patient

Exclusion criteria

* association of gamaknife radiosurgery and microsurgery resection * bilateral vestibular schwannoma

Design outcomes

Primary

MeasureTime frameDescription
Vestibular evaluation DHIFrom 4 years to 6 monthsThe investigator use a standarised scale : \- Dizziness Handicap Inventory (DHI). This scale combines 25 questions with three answers for each proposition about dizzyness in daily life situation : everytime (quote 4), sometimes (quote 2), never (quote 0). The scores are summing to obtain a value on 100. The scale is completed before and after the treatement. The investigator send the scale to the patient by mail way.
Vestibular evaluation AAOFrom 4 years to 6 monthsThe investigator use a standarised scale : \- Dizziness Functionnal Scale (AAO), this is a scale quote from 1 (no symptoms of dizzyness) to 6 (major disability). The patient have to choise only one item that correspond to the condition. The scale is completed before and after the treatement. The investigator send the scale to the patient by mail way.

Secondary

MeasureTime frameDescription
Facial fonctionFrom 4 years to 6 monthsHouse and Brackmann scale : This scale is a standarised assessment of facial fonction from grade I : normal ; to grade VI : total paralysis. Each scale is completed after the treatement.
Hearing functionFrom 4 years to 6 monthsThis information is based on a question to the patient about the usefulness of hearing prothesis. So there are 2 groups : useful hearing (normal hearing or used hearing prothesis) or useless hearing (unsused hearing prothesis) The information is completed before and after the treatement.
Tumor controlFrom 4 years to 6 monthsTumor control is based on MRI size description (in mm): So there are 2 groups : controled or evolution of the tumor. * for microsurgery resection group the investigator keeps interest about the remaining size * for radiosurgery gammaknife group the investigator keeps interest about the stability or the reduction of the tumor The result is completed after the treatement.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026